Toshiaki Takeda, the former Factory Manager ... and is gaining confidence each time he steps behind the wheel of this car. Hiroki Otsu’s relative experience and adaptability will only continue to ...

Novavax, Inc. has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, ...

TOKYO (dpa-AFX) - Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

India may soon mark a major milestone in its fight against dengue with the anticipated rollout of the Japanese-developed vaccine Qdenga. With plans for domestic production underway, the vaccine ...

OSAKA, Japan and CAMBRIDGE, Massachusetts, April 25, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

Takeda must continue to demonstrate value through outcome-based contracts and cost-effectiveness data. As newer agents with novel mechanisms enter the market, maintaining differentiation and ...

Takeda has announced a $100 million collaboration with Abingworth to work with GammaDelta Therapeutics, a UK biotech which is pioneering a novel type of T cell therapy. The Japanese pharma company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...